Precision Pharmacology in Multiple Sclerosis: Optimizing Drug Development and Personalized Treatment

Jump To Section

• What is Precision Pharmacology?
• Core Principles of Precision Pharmacology
• Role in MS Drug Development
• Molecular Imaging and Target Engagement
• Guiding Personalized MS Therapy
• Full Transcript

What is Precision Pharmacology?

Precision pharmacology is a fundamental concept in modern pharmaceutical science. According to Dr. Paul Matthews, MD, it represents a strategic reworking of core pharmacological principles. The approach focuses on ensuring a therapeutic molecule interacts with its intended biological target under optimal conditions.

Dr. Matthews describes it as the essential flip side of the more widely known concept of precision medicine. While precision medicine concentrates on treating the individual patient, precision pharmacology is concerned with how medications are used across entire patient populations. This distinction is critical for effective drug development and deployment in complex conditions like multiple sclerosis.

Core Principles of Precision Pharmacology

The framework of precision pharmacology rests on four critical pillars for successful treatment. Dr. Paul Matthews, MD, emphasizes that a medication must hit the correct biological target. It must do so at the correct time in the disease process and to the exact level required for therapeutic effect.

Most importantly, the medication must be administered to the correct patient population. Satisfying all these criteria simultaneously is the ultimate goal of precision pharmacology. This multi-faceted approach helps mitigate the risk of drug failure during the expensive and lengthy development process.

Role in MS Drug Development

Precision pharmacology plays a vital role in the multiple sclerosis medication development pipeline. Dr. Paul Matthews, MD, highlights its importance in building confidence during the pharmaceutical development path. This is especially crucial given the enormous costs often associated with translating basic research discoveries into clinical applications.

Dr. Paul Matthews, MD, explains that this approach provides early evidence of a medication's potential value. It helps researchers and developers understand whether a drug will truly benefit patients before it completes the full development and testing process. This early validation is key to avoiding costly late-stage failures in MS drug development.

Molecular Imaging and Target Engagement

Advanced imaging technologies are fundamental tools in precision pharmacology. Dr. Paul Matthews, MD, specifically mentions human in vivo molecular imaging with positron emission tomography (PET) as a cornerstone technology. These imaging modalities provide direct visual evidence of whether a medication successfully engages its intended target.

Dr. Matthews stresses that these measures help researchers understand the extent of target engagement. They also reveal whether the medication is having the expected impact on disease pathology. This real-time feedback is invaluable for optimizing dosing regimens and confirming biological activity early in development.

Guiding Personalized MS Therapy

Precision pharmacology ultimately serves to guide personalized treatment strategies for multiple sclerosis patients. Dr. Paul Matthews, MD, explains how this approach helps clinicians make informed hypotheses about which patients will benefit from specific medications. It provides the scientific rationale for stratified therapy in MS.

During his discussion with Dr. Anton Titov, MD, Dr. Matthews emphasized that precision pharmacology helps understand why certain patients respond to treatment while others may not. This knowledge is crucial for moving beyond one-size-fits-all approaches and toward truly personalized medicine for multiple sclerosis and other neurological conditions.

Full Transcript

Dr. Anton Titov, MD: Precision pharmacology. You led the multiple sclerosis clinical program at a major pharmaceutical company, so you have very intricate knowledge of the challenges in the multiple sclerosis medication development process.

Dr. Paul Matthews, MD: There are enormous costs that often prevent very promising basic research discoveries from making the proverbial leap from bench to bedside.

Dr. Anton Titov, MD: You recently used the term "precision pharmacology" to describe human in vivo molecular imaging with positron emission tomography. What is precision pharmacology? How does it help the modern multiple sclerosis medication development process? Maybe you can provide an example of precision pharmacology use?

Dr. Paul Matthews, MD: Precision pharmacology is a slight reworking of a very fundamental concept of pharmacology. This means we need to have a molecule that hits the correct target, at the correct time, to the correct level, and in the correct patient. Precision pharmacology is satisfying all of these criteria simultaneously.

This is the reason for the importance of the precision pharmacology concept. It is the flip side of precision medicine or personalized medicine.

Dr. Paul Matthews, MD: It is saying, "Let's think about how we use multiple sclerosis medications in the population, as opposed to how we treat individual patients." The concepts of precision pharmacology and precision medicine are intimately related, but they are slightly different problems.

Precision pharmacology is based around having measures that help us understand whether we have engaged the target of medication. It helps us to understand whether we have engaged the target to the right extent.

Whether medication is having the impact that we expected it to have on pathology. Precision pharmacology helps us to understand whether medication is potentially benefiting that particular patient within a patient group.

Precision pharmacology is a part of the early multiple sclerosis medication development process. It helps us gain confidence during the pharmaceutical development path.

We will know whether a multiple sclerosis medication will have value for patients when medication is used in clinical practice, when medication has completed the process of pharmaceutical development and testing.

This is a reason why precision pharmacology will be important in the future. It is a way of making sure that we do not encounter key problems in multiple sclerosis medication development.

It helps to also provide evidence of the value of the medication when physicians start to use it.

Dr. Paul Matthews, MD: Finally, precision pharmacology helps us to guide personalized therapy or stratified therapy in multiple sclerosis. We can observe the medication’s use by the clinicians.

Precision pharmacology helps us to make hypotheses about the patients who will benefit from a medication. We can understand why patients benefit from a particular medication.

Dr. Anton Titov, MD: Professor Matthews, thank you very much for this very fascinating conversation about brain imaging. It was useful to discuss multiple sclerosis and the latest trends in development of treatment for multiple sclerosis.

Dr. Paul Matthews, MD: Thank you for discussing in detail the research use of functional MRI and other sophisticated MRI technologies that you are developing. We really appreciate your time.

Dr. Anton Titov, MD: I'm sure that it will be very interesting for viewers around the world to learn about the latest in brain imaging technologies and multiple sclerosis treatment. Thank you very much!

Dr. Paul Matthews, MD: Thank you, Anton. It is nice speaking with you! Thank you!